Patients with juvenile idiopathic arthritis achieved long-term disease control with subcutaneous tocilizumab treatment, without any new safety concerns, in an LTE study of two trials.
Longer tocilizumab administration intervals and lower prednisolone doses seemed pivotal for successful tocilizumab withdrawal while maintaining remission in patients with AOSD.